This Elitek or Fasturtec market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
Market growth during the historic period can be attributed to the increasing prevalence of tumor lysis syndrome in adults, a rising incidence of non-Hodgkin lymphoma and solid tumor malignancies, the growing occurrence of elevated uric acid levels in cancer patients, the global rise in cancer cases, and the increase in high uric acid levels due to chemotherapy.
The projected growth for the forecast period is driven by the growing demand for novel treatments and technologies, a rising number of regulatory approvals and expanded indications, improvements in healthcare policies and insurance coverage for cancer treatments, an increase in cases of leukemia, lymphoma, and other cancers, and greater awareness and early diagnosis of tumor lysis syndrome. Key trends include the development of new formulations and dosage forms, the creation of more effective and personalized treatment methods, advances in telemedicine and remote patient monitoring, strategic partnerships between pharmaceutical companies and research institutions, and favorable policies and insurance coverage for cancer treatments.
The growing prevalence of leukemia is expected to drive the expansion of the elitek (fasturtec) market. Leukemia is characterized by the uncontrolled growth of abnormal white blood cells in the bone marrow, often triggered by genetic mutations, environmental factors, or exposure to radiation and certain chemicals. The incidence of leukemia is rising due to factors such as aging populations, genetic predispositions, environmental exposures, and advancements in diagnostic technologies. Elitek (Fasturtec) helps manage leukemia by lowering high uric acid levels associated with tumor lysis syndrome (TLS), a condition that arises when cancer treatments rapidly destroy leukemia cells, releasing large amounts of uric acid into the bloodstream. For example, the American Cancer Society reported in 2024 that leukemia cases had increased to 62,770, up from 59,610 in 2023. Therefore, the rising prevalence of leukemia is driving the growth of the elitek (fasturtec) market.
The increasing emphasis on personalized medicine is expected to support the growth of the elitek (fasturtec) market. Personalized medicine is a healthcare approach that tailors treatments and therapies based on an individual’s genetic makeup, environment, and lifestyle. This approach is gaining momentum due to advances in genomic medicine, the rise of chronic diseases, better diagnostic tools, and a shift toward more patient-centered care. Elitek (Fasturtec) serves as a form of personalized medicine by managing elevated uric acid levels in individual cancer patients at risk of TLS, adjusting treatment according to specific factors such as cancer type, chemotherapy regimen, and patient response. In February 2024, the Personalized Medicine Coalition reported that the FDA had approved 16 new personalized treatments for rare diseases in 2023, a significant increase from the six approvals in 2022. As such, the growing focus on personalized medicine is contributing to the expansion of the elitek (fasturtec) market.
A key trend in the elitek (fasturtec) market is the broadening of its use to adult patients, particularly for managing tumor lysis syndrome (TLS) in cancer patients. TLS is becoming more common among individuals undergoing chemotherapy for aggressive cancers such as leukemia, lymphoma, and solid tumors, leading to an increased demand for effective treatments. Companies in this sector are working to expand their products' applications beyond pediatric patients, aiming to target a wider range of cancer treatments. In October 2023, Sanofi S.A., a France-based pharmaceutical company, received FDA approval for Elitek to manage plasma uric acid levels in adult leukemia, lymphoma, and solid tumor patients undergoing cancer treatment that may lead to TLS. This approval was supported by Phase 3 trial results showing that Elitek significantly reduced uric acid levels compared to oral allopurinol in adults at risk for TLS, providing a crucial treatment for this potentially life-threatening condition.
The key company operating in the elitek or fasturtec market is Sanofi S.A.
North America was the largest region in the elitek or fasturtec market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in elitek or fasturtec report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the elitek Or fasturtec market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Elitek (known as Fasturtec outside the US) is a medication containing rasburicase, used to treat or prevent elevated uric acid levels resulting from tumor lysis syndrome (TLS) in cancer patients undergoing chemotherapy. It works by converting uric acid into allantoin, which is more easily eliminated by the kidneys, thereby reducing the risk of kidney damage. Administered intravenously, Elitek is particularly important for patients with leukemia, lymphoma, or other cancers that rapidly release uric acid during treatment.
The primary dosage forms of elitek (or Fasturtec) are injectable and lyophilized powder. Elitek (rasburicase) injectable is a prescription medication designed to manage high uric acid levels (hyperuricemia) caused by cancer treatments in patients with leukemia, lymphoma, or other malignancies. Key indications include tumor lysis syndrome (TLS) and other related conditions. It is used by both pediatric and adult patients, and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies. Elitek is utilized in hospitals, clinics, ambulatory care settings, and for home care.
The elitek or fasturtec market research report is one of a series of new reports that provides elitek or fasturtec market statistics, including the elitek or fasturtec industry global market size, regional shares, competitors with the elitek or fasturtec market share, detailed elitek or fasturtec market segments, market trends, and opportunities, and any further data you may need to thrive in the elitek or fasturtec industry. This elitek or fasturtec market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The elitek or fasturtec market consists of sales of supportive medications and combination therapy kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Market growth during the historic period can be attributed to the increasing prevalence of tumor lysis syndrome in adults, a rising incidence of non-Hodgkin lymphoma and solid tumor malignancies, the growing occurrence of elevated uric acid levels in cancer patients, the global rise in cancer cases, and the increase in high uric acid levels due to chemotherapy.
The projected growth for the forecast period is driven by the growing demand for novel treatments and technologies, a rising number of regulatory approvals and expanded indications, improvements in healthcare policies and insurance coverage for cancer treatments, an increase in cases of leukemia, lymphoma, and other cancers, and greater awareness and early diagnosis of tumor lysis syndrome. Key trends include the development of new formulations and dosage forms, the creation of more effective and personalized treatment methods, advances in telemedicine and remote patient monitoring, strategic partnerships between pharmaceutical companies and research institutions, and favorable policies and insurance coverage for cancer treatments.
The growing prevalence of leukemia is expected to drive the expansion of the elitek (fasturtec) market. Leukemia is characterized by the uncontrolled growth of abnormal white blood cells in the bone marrow, often triggered by genetic mutations, environmental factors, or exposure to radiation and certain chemicals. The incidence of leukemia is rising due to factors such as aging populations, genetic predispositions, environmental exposures, and advancements in diagnostic technologies. Elitek (Fasturtec) helps manage leukemia by lowering high uric acid levels associated with tumor lysis syndrome (TLS), a condition that arises when cancer treatments rapidly destroy leukemia cells, releasing large amounts of uric acid into the bloodstream. For example, the American Cancer Society reported in 2024 that leukemia cases had increased to 62,770, up from 59,610 in 2023. Therefore, the rising prevalence of leukemia is driving the growth of the elitek (fasturtec) market.
The increasing emphasis on personalized medicine is expected to support the growth of the elitek (fasturtec) market. Personalized medicine is a healthcare approach that tailors treatments and therapies based on an individual’s genetic makeup, environment, and lifestyle. This approach is gaining momentum due to advances in genomic medicine, the rise of chronic diseases, better diagnostic tools, and a shift toward more patient-centered care. Elitek (Fasturtec) serves as a form of personalized medicine by managing elevated uric acid levels in individual cancer patients at risk of TLS, adjusting treatment according to specific factors such as cancer type, chemotherapy regimen, and patient response. In February 2024, the Personalized Medicine Coalition reported that the FDA had approved 16 new personalized treatments for rare diseases in 2023, a significant increase from the six approvals in 2022. As such, the growing focus on personalized medicine is contributing to the expansion of the elitek (fasturtec) market.
A key trend in the elitek (fasturtec) market is the broadening of its use to adult patients, particularly for managing tumor lysis syndrome (TLS) in cancer patients. TLS is becoming more common among individuals undergoing chemotherapy for aggressive cancers such as leukemia, lymphoma, and solid tumors, leading to an increased demand for effective treatments. Companies in this sector are working to expand their products' applications beyond pediatric patients, aiming to target a wider range of cancer treatments. In October 2023, Sanofi S.A., a France-based pharmaceutical company, received FDA approval for Elitek to manage plasma uric acid levels in adult leukemia, lymphoma, and solid tumor patients undergoing cancer treatment that may lead to TLS. This approval was supported by Phase 3 trial results showing that Elitek significantly reduced uric acid levels compared to oral allopurinol in adults at risk for TLS, providing a crucial treatment for this potentially life-threatening condition.
The key company operating in the elitek or fasturtec market is Sanofi S.A.
North America was the largest region in the elitek or fasturtec market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in elitek or fasturtec report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the elitek Or fasturtec market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Elitek (known as Fasturtec outside the US) is a medication containing rasburicase, used to treat or prevent elevated uric acid levels resulting from tumor lysis syndrome (TLS) in cancer patients undergoing chemotherapy. It works by converting uric acid into allantoin, which is more easily eliminated by the kidneys, thereby reducing the risk of kidney damage. Administered intravenously, Elitek is particularly important for patients with leukemia, lymphoma, or other cancers that rapidly release uric acid during treatment.
The primary dosage forms of elitek (or Fasturtec) are injectable and lyophilized powder. Elitek (rasburicase) injectable is a prescription medication designed to manage high uric acid levels (hyperuricemia) caused by cancer treatments in patients with leukemia, lymphoma, or other malignancies. Key indications include tumor lysis syndrome (TLS) and other related conditions. It is used by both pediatric and adult patients, and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies. Elitek is utilized in hospitals, clinics, ambulatory care settings, and for home care.
The elitek or fasturtec market research report is one of a series of new reports that provides elitek or fasturtec market statistics, including the elitek or fasturtec industry global market size, regional shares, competitors with the elitek or fasturtec market share, detailed elitek or fasturtec market segments, market trends, and opportunities, and any further data you may need to thrive in the elitek or fasturtec industry. This elitek or fasturtec market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The elitek or fasturtec market consists of sales of supportive medications and combination therapy kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Elitek or Fasturtec Market Characteristics4. Elitek or Fasturtec Market Trends and Strategies5. Elitek or Fasturtec Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Elitek or Fasturtec Pricing Analysis & Forecasts30. Global Elitek or Fasturtec Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Elitek or Fasturtec Market32. Recent Developments in the Elitek or Fasturtec Market
3. Elitek or Fasturtec Market Biologic Drug Characteristics
6. Global Elitek or Fasturtec Growth Analysis and Strategic Analysis Framework
8. Elitek or Fasturtec Market Segmentation
9. Global Elitek or Fasturtec Epidemiology of Clinical Indications
10. Elitek or Fasturtec Market Regional and Country Analysis
11. Asia-Pacific Elitek or Fasturtec Market
12. China Elitek or Fasturtec Market
13. India Elitek or Fasturtec Market
14. Japan Elitek or Fasturtec Market
15. Australia Elitek or Fasturtec Market
16. South Korea Elitek or Fasturtec Market
17. Western Europe Elitek or Fasturtec Market
18. UK Elitek or Fasturtec Market
19. Germany Elitek or Fasturtec Market
20. France Elitek or Fasturtec Market
21. Eastern Europe Elitek or Fasturtec Market
22. North America Elitek or Fasturtec Market
23. USA Elitek or Fasturtec Market
24. Canada Elitek or Fasturtec Market
25. South America Elitek or Fasturtec Market
26. Middle East Elitek or Fasturtec Market
27. Africa Elitek or Fasturtec Market
28. Elitek or Fasturtec Market Competitive Landscape and Company Profiles
29. Global Elitek or Fasturtec Market Pipeline Analysis
33. Elitek or Fasturtec Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Elitek or Fasturtec Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on elitek or fasturtec market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for elitek or fasturtec? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The elitek or fasturtec market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Dosage Form: Injectable; Lyophilized Powder2) by Indication: Tumor Lysis Syndrome (TLS); Other Indications
3) by Patient Type: Pediatric Patients; Adult Patients
4) by Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
5) by End Use: Hospitals; Clinics; Ambulatory Care; Home Care
Key Companies Mentioned: Sanofi S.a.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Sanofi S.A.
